Pub Date : 2021-04-15DOI: 10.1007/s10766-021-00713-2
Iraklis M. Spiliotis, Charalampos Sitaridis, M. P. Bekakos
{"title":"Parallel Computation of Discrete Orthogonal Moment on Block Represented Images Using OpenMP","authors":"Iraklis M. Spiliotis, Charalampos Sitaridis, M. P. Bekakos","doi":"10.1007/s10766-021-00713-2","DOIUrl":"https://doi.org/10.1007/s10766-021-00713-2","url":null,"abstract":"","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"49 1","pages":"440 - 462"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10766-021-00713-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43607676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.015
Amol Deore, Vijay Ahirrao
Crigler-Najjar Syndrome type 2 [CN-2] is an uncommon inherited disorder characterized by non-hemolytic unconjugated hyperbilirubinemia. It is caused by mutations in one of the five exons of the UGT1A1 gene which codes for the enzyme hepatic uridine diphosphate glucoronosyl transferase-1, required for the conjugation and further excretion of bilirubin from the body via bile. Affected people are usually asymptomatic apart from jaundice and investigations reveal isolated indirect hyperbilirubinemia. It can be conveniently diagnosed by evaluating the response to phenobarbital in terms of reduction in bilirubin levels. Genetic testing confirms the finding of Crigler-Najjar syndrome. At least 20 different mutations of UGT1A1 have been associated with CN-2; all encode a bilirubin-uridine diphosphate glucuronosyl transferase-1 with markedly reduced but detectable enzymatic activity. Bilirubin concentrations are typically lower in CN-2, and plasma bilirubin levels can be reduced to 3 to 5 mg/dL by phenobarbital. Although uncommon in CN-2, bilirubin encephalopathy has occurred at all ages, typically associated with factors that temporarily elevation the plasma bilirubin concentration above baseline e.g. stress, prolonged fasting, an intercurrent illness like influenza. For this reason, phenobarbital therapy is often recommended. CN-2 is infrequent, and only a few pregnancies with this condition have been reported. The objective of the case study is to report a rare case of maternal CN-2 in the pregnancy and to evaluate whether pregnancy is safe in patients with the disease. A 29 years old mother with CN-2 had given birth to a baby girl by spontaneous vaginal delivery without complications. The newborn had mild unconjugated hyperbilirubinemia which was further treated by phototherapy and early morning sunlight. It can be concluded that that pregnancy need not be contraindicated in CN-2. Keywords: Hyperbilirubinemia, Phototherapy, UGT1A1 gene, Jaundice, Glucuronidation.
{"title":"Maternal outcome of Crigler-Najjar syndrome type-2: Case report","authors":"Amol Deore, Vijay Ahirrao","doi":"10.18231/J.IJPP.2021.015","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.015","url":null,"abstract":"Crigler-Najjar Syndrome type 2 [CN-2] is an uncommon inherited disorder characterized by non-hemolytic unconjugated hyperbilirubinemia. It is caused by mutations in one of the five exons of the UGT1A1 gene which codes for the enzyme hepatic uridine diphosphate glucoronosyl transferase-1, required for the conjugation and further excretion of bilirubin from the body via bile. Affected people are usually asymptomatic apart from jaundice and investigations reveal isolated indirect hyperbilirubinemia. It can be conveniently diagnosed by evaluating the response to phenobarbital in terms of reduction in bilirubin levels. Genetic testing confirms the finding of Crigler-Najjar syndrome. At least 20 different mutations of UGT1A1 have been associated with CN-2; all encode a bilirubin-uridine diphosphate glucuronosyl transferase-1 with markedly reduced but detectable enzymatic activity. Bilirubin concentrations are typically lower in CN-2, and plasma bilirubin levels can be reduced to 3 to 5 mg/dL by phenobarbital. Although uncommon in CN-2, bilirubin encephalopathy has occurred at all ages, typically associated with factors that temporarily\u0000elevation the plasma bilirubin concentration above baseline e.g. stress, prolonged fasting, an intercurrent illness like influenza. For this reason, phenobarbital therapy is often recommended. CN-2 is infrequent, and only a few pregnancies with this condition have been reported. The objective of the case study is to report a rare case of maternal CN-2 in the pregnancy and to evaluate whether pregnancy is safe in patients with the disease. A 29 years old mother with CN-2 had given birth to a baby girl by spontaneous vaginal delivery without complications. The newborn had mild unconjugated hyperbilirubinemia which was further treated by phototherapy and early morning sunlight. It can be concluded that that pregnancy need not be contraindicated in CN-2.\u0000\u0000Keywords: Hyperbilirubinemia, Phototherapy, UGT1A1 gene, Jaundice, Glucuronidation.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"92-96"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49380821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.009
I. Khan, M. Nasiruddin, S. Arif
Objectives: Hepatotoxicity occurs as a side effect of first line anti-tubercular drug such as Isoniazid. The aim of the present study was to evaluate therapeutic potential of ethanolic extract of Rosa damascene flowers (RDEE) in isoniazid induced hepatotoxicity in rats. Methods: Rats were given orally isoniazid (50 mg/kg) for 28 days. Silymarin (50 mg/kg) was administered, as standard drug. From 29th to 43rd day of the study, isoniazid was stopped and therapeutic agents such as normal saline, silymarin, RDEE 1.5g/kg and 3g/kg were given orally in different animal groups respectively. On 44th day, blood samples were collected for biochemical analysis and liver tissue was subjected to histopathological examination. Results: The rats administered RDEE showed significant reduction in the liver marker enzymes and total bilirubin treated as compared to negative control group. There was also significant improvement in antioxidant levels and histopathological scores in RDEE treated group in comparison to the negative control group. Conclusion: This study demonstrates the beneficial effect of ethanolic extract of Rosa damascene flowers (RDEE) as a therapeutic agent in hepatotoxicity induced by isoniazid in a dose dependant manner. Keywords: Rosa damascene, Hepatoprotective, Isoniazid, Silymarin, Tuberculosis, Hepatotoxicity.
{"title":"An experimental evaluation of therapeutic effect of Rosa damascena in hepatotoxicity induced by isoniazid","authors":"I. Khan, M. Nasiruddin, S. Arif","doi":"10.18231/J.IJPP.2021.009","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.009","url":null,"abstract":"Objectives: Hepatotoxicity occurs as a side effect of first line anti-tubercular drug such as Isoniazid. The aim of the present study was to evaluate therapeutic potential of ethanolic extract of Rosa damascene flowers (RDEE) in isoniazid induced hepatotoxicity in rats.\u0000Methods: Rats were given orally isoniazid (50 mg/kg) for 28 days. Silymarin (50 mg/kg) was administered, as standard drug. From 29th to 43rd day of the study, isoniazid was stopped and therapeutic agents such as normal saline, silymarin, RDEE 1.5g/kg and 3g/kg were given orally in different animal groups respectively. On 44th day, blood samples were collected for biochemical analysis and liver tissue was subjected to histopathological examination.\u0000Results: The rats administered RDEE showed significant reduction in the liver marker enzymes and total bilirubin treated as compared to negative control group. There was also significant improvement in antioxidant levels and histopathological scores in RDEE treated group in comparison to the negative control group.\u0000Conclusion: This study demonstrates the beneficial effect of ethanolic extract of Rosa damascene flowers (RDEE) as a therapeutic agent in hepatotoxicity induced by isoniazid in a dose dependant manner.\u0000\u0000Keywords: Rosa damascene, Hepatoprotective, Isoniazid, Silymarin, Tuberculosis, Hepatotoxicity.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"52-57"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45244844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.012
A. Agrawal, A. Mehta
Now a day most of the patients on long term therapy of glucocorticoid become insensitive to corticosteroids and addition of vitamin D to such patients may enhance to response to corticosteroids. Therefore, we investigated anti-inflammatory activity of vitamin D in presence of glucocorticoids receptor antagonist; mifepristone, to assess whether, vitamin D acts as dependent or independently from glucocorticoids receptor. Wistar albino rats were sensitized with ovalbumin (OVA) and, upon OVA challenge, developed airway eosinophilia and neutrophilia. Administration of dextamethasone, vitamin D and combination of dextamethasone+vitamin D, and dextamethasone+vitamin D+mifepristone significantly (P Keywords: Asthma, Vitamin D, Mifepristone.
{"title":"Vitamin D acts as independently from glucocorticoid receptor in animal model of asthma","authors":"A. Agrawal, A. Mehta","doi":"10.18231/J.IJPP.2021.012","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.012","url":null,"abstract":"Now a day most of the patients on long term therapy of glucocorticoid become insensitive to corticosteroids and addition of vitamin D to such patients may enhance to response to corticosteroids. Therefore, we investigated anti-inflammatory activity of vitamin D in presence of glucocorticoids receptor antagonist; mifepristone, to assess whether, vitamin D acts as dependent or independently from glucocorticoids receptor. Wistar albino rats were sensitized with ovalbumin (OVA) and, upon OVA challenge, developed\u0000airway eosinophilia and neutrophilia. Administration of dextamethasone, vitamin D and combination of dextamethasone+vitamin D, and dextamethasone+vitamin D+mifepristone significantly (P\u0000\u0000Keywords: Asthma, Vitamin D, Mifepristone.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"74-77"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47983977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.011
C. Upasani, Manoj Mahajan, A. Upaganlawar
Introduction: Diabetic nephropathy (DN) has been recognized as the one of the microvascular chronic complications resulting from diabetes. Though, efforts have taken to develop effective therapies for attenuation of DN, involvement of the multiple pathogenetic mechanisms and underlying oxidative stress (OS) makes it difficult to choose optimum therapeutic agent. Objective: The study is aimed at assessing the possible therapeutic effect of coenzyme Q10 (CoQ10) and N-acetylcysteine (NAC) individually or in combination on experimental DN in rats. Materials and Methods: The study was performed on adult male Sprague Dawley rats (n = 50; 200–250 g). Rats were made diabetic by alloxan (130 mg/kg; i.p.). The non-diabetic rats were randomly assigned to control, CoQ10 (10 mg/kg, p.o.), NAC (300 mg/kg, p.o.), and CoQ10+ NAC group. Whereas diabetic rats were grouped as DN control, DN+ CoQ10, DN+ NAC and DN+ CoQ10 +NAC groups. CoQ10 and/or NAC were administered to the diabetic rats for 8 weeks after confirmation of the DN. Renal functions and tissue antioxidant parameters were estimated. Results: Renal function tests and urinary proteins were significantly (p Conclusion: The study provides valuable information supporting that treatment with combination of CoQ10 and NAC might prevent or delay the renal damage associated with DN and improves the antioxidant. Keywords: Diabetic nephropathy, Coenzyme Q10, N-acetylcysteine, Oxidative stress, Alloxan.
{"title":"The effect of co-enzyme Q10 and N-acetylcysteine on biochemical parameters and oxidative stress in rats subjected to alloxan induced diabetic nephropathy","authors":"C. Upasani, Manoj Mahajan, A. Upaganlawar","doi":"10.18231/J.IJPP.2021.011","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.011","url":null,"abstract":"Introduction: Diabetic nephropathy (DN) has been recognized as the one of the microvascular chronic complications resulting from diabetes. Though, efforts have taken to develop effective therapies for attenuation of DN, involvement of the multiple pathogenetic mechanisms and underlying oxidative stress (OS) makes it difficult to choose optimum therapeutic agent.\u0000Objective: The study is aimed at assessing the possible therapeutic effect of coenzyme Q10 (CoQ10) and N-acetylcysteine (NAC) individually or in combination on experimental DN in rats.\u0000Materials and Methods: The study was performed on adult male Sprague Dawley rats (n = 50; 200–250 g). Rats were made diabetic by alloxan (130 mg/kg; i.p.). The non-diabetic rats were randomly assigned to control, CoQ10 (10 mg/kg, p.o.), NAC (300 mg/kg, p.o.), and CoQ10+ NAC group. Whereas diabetic rats were grouped as DN control, DN+ CoQ10, DN+ NAC and DN+ CoQ10 +NAC groups. CoQ10 and/or NAC were administered to the diabetic rats for 8 weeks after confirmation of the DN. Renal functions and tissue antioxidant parameters were estimated.\u0000Results: Renal function tests and urinary proteins were significantly (p Conclusion: The study provides valuable information supporting that treatment with combination of CoQ10 and NAC might prevent or delay the renal damage associated with DN and improves the antioxidant.\u0000\u0000Keywords: Diabetic nephropathy, Coenzyme Q10, N-acetylcysteine, Oxidative stress, Alloxan.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"65-73"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46312242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.006
D. Kansal, N. Patiyal, A. Bhardwaj, A. Sood, Sushma Sawaraj, Ankit Chauhan, Palvi Mittal
Background: Carbamazepine is used widely in focal seizures but has the disadvantage of frequent drug interactions. Levetiracetam is a novel antiseizure drug with better pharmacokinetic profile with less drug interactions and having broader therapeutic range. Aims: The aim of our study was to generate more evidence for better management of focal seizures with available anti-seizure monotherapy. Materials and Methods: It was a randomized, prospective, open label, comparative interventional study, conducted at Dr. R.P.G.M.C, Kangra at Tanda. 38 participants received tablet levetiracetam (LEV) 1000 mg/day and 36 participants received tablet controlled-release carbamazepine (CBZ-CR) 600 mg/day. Results: CBZ-CR group had significantly higher CNS depression as compared to LEV (p=0.027). Hematological adverse effects with CBZ-CR were reversible. Both the drugs were safe on kidney and liver. 22 (66.7%) patients in LEV group and 26 (78.8%) in CBZ-CR group remained seizure free. QOL: Both the drugs significantly improved QOL. Pharmacoeconomics: CBZ-CR costed significantly lower than LEV (p Conclusion: Both the drugs are well tolerated and equally efficacious in controlling focal seizures. Quality of- life has improved significantly in both the groups. CBZ-CR is pharmacoeconomically better than LEV for treatment of new onset focal seizures in adult patients. Keywords: Controlled release carbamazepine, Epilepsy, Focal seizure, Levetiracetam, Pharmacoeconomics.
{"title":"A comparative study of the safety, efficacy, quality of life and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in patients of new onset focal seizures: A randomized controlled academic trial","authors":"D. Kansal, N. Patiyal, A. Bhardwaj, A. Sood, Sushma Sawaraj, Ankit Chauhan, Palvi Mittal","doi":"10.18231/J.IJPP.2021.006","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.006","url":null,"abstract":"Background: Carbamazepine is used widely in focal seizures but has the disadvantage of frequent drug interactions. Levetiracetam is a novel antiseizure drug with better pharmacokinetic profile with less drug interactions and having broader therapeutic range.\u0000Aims: The aim of our study was to generate more evidence for better management of focal seizures with available anti-seizure monotherapy.\u0000Materials and Methods: It was a randomized, prospective, open label, comparative interventional study, conducted at Dr. R.P.G.M.C, Kangra at Tanda. 38 participants received tablet levetiracetam (LEV) 1000 mg/day and 36 participants received tablet controlled-release carbamazepine (CBZ-CR) 600 mg/day.\u0000Results: CBZ-CR group had significantly higher CNS depression as compared to LEV (p=0.027). Hematological adverse effects with CBZ-CR were reversible. Both the drugs were safe on kidney and liver. 22 (66.7%) patients in LEV group and 26 (78.8%) in CBZ-CR group remained seizure free. QOL: Both the drugs significantly improved QOL. Pharmacoeconomics: CBZ-CR costed significantly lower than LEV (p\u0000Conclusion: Both the drugs are well tolerated and equally efficacious in controlling focal seizures. Quality of- life has improved significantly in both the groups. CBZ-CR is pharmacoeconomically better than LEV for treatment of new onset focal seizures in adult patients.\u0000\u0000Keywords: Controlled release carbamazepine, Epilepsy, Focal seizure, Levetiracetam, Pharmacoeconomics.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"35-41"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49224491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.003
Motghare Vijay M, Ingale Nikita S, Turankar Avinash V, Wagh Mitali S
Background: Diabetes Mellitus is a spreading pandemic to the countries around the globe, despite of scientific breakthroughs and better healthcare facilities. Sodium-Glucose Co-Transporter Type 2 inhibitors (SGLT2i) are the latest class of oral anti-hyperglycemic agents that have been approved for the treatment of type II diabetes mellitus. Aim: In this review, we have comprehended the evidence for antidiabetic and extra-glycaemic effects of SGLT2i. Materials and Methods: The information is collected based on safety trials, randomized controlled trials (RCT), meta-analyses and real-world data. Results: SGLT2i are rapidly establishing their role in the treatment of diabetes mellitus. The beneficial effects extend beyond glycaemic control, impressive cardio protective and Reno protective effects and included improvement in blood pressure, uric acid concentrations, body weight and oxidative stress. Conclusion: Especially in patients with type 2 diabetes, SGLT2 inhibitors may be another option in those patients requiring additional glucose lowering and in those with acceptable risk factors. More research on the long term outcomes of SGLT2i is warranted. Keywords: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Sodium-glucose cotransporter-2 inhibitors, Sotagliflozin, Type 2 diabetes mellitus.
{"title":"Current status of Sodium-Glucose Co-Transporter Type 2 (SGLT2) inhibitors in treating diabetes mellitus","authors":"Motghare Vijay M, Ingale Nikita S, Turankar Avinash V, Wagh Mitali S","doi":"10.18231/J.IJPP.2021.003","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.003","url":null,"abstract":"Background: Diabetes Mellitus is a spreading pandemic to the countries around the globe, despite of scientific breakthroughs and better healthcare facilities. Sodium-Glucose Co-Transporter Type 2 inhibitors (SGLT2i) are the latest class of oral anti-hyperglycemic agents that have been approved for the treatment of type II diabetes mellitus.\u0000Aim: In this review, we have comprehended the evidence for antidiabetic and extra-glycaemic effects of SGLT2i.\u0000Materials and Methods: The information is collected based on safety trials, randomized controlled trials (RCT), meta-analyses and real-world data.\u0000Results: SGLT2i are rapidly establishing their role in the treatment of diabetes mellitus. The beneficial effects extend beyond glycaemic control, impressive cardio protective and Reno protective effects and included improvement in blood pressure, uric acid concentrations, body weight and oxidative stress.\u0000Conclusion: Especially in patients with type 2 diabetes, SGLT2 inhibitors may be another option in those patients requiring additional glucose lowering and in those with acceptable risk factors. More research on the long term outcomes of SGLT2i is warranted.\u0000\u0000Keywords: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Sodium-glucose cotransporter-2 inhibitors, Sotagliflozin, Type 2 diabetes mellitus.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"10-16"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49603143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-15DOI: 10.18231/J.IJPP.2021.008
Dhavalkumar Patel, Devnaad Singh, Biraju Patel, C. Borkhataria
An alleviation of patient wellness and safety, the pharmaceutical ecotechnology play crucial role by eliminating the threat of counterfeit drugs, medicines and drug adulteration. The numerous issue of supply chain such as production of inferior copy of branded product with label of the original brand name, the risk of putting wrong product into distribution, unauthorized distribution of branded product and lack of consistency across countries are now a days creating challenges for pharmaceutical manufacturers worldwide. The regulatory authorities of countries and pharmaceutical industries believe that serialization and product tracking could be the ultimate solution for these worldwide issues. Serialization system has the capacity to find out current and past locations of the product through entire supply chain. Hence, due to urgent necessity in today’s competitive environment, the implementation of this technology has found to be more effective to enhance counterfeit prevention, pilferage reduction and targeted recalls as well as improve security, visibility, synchronization and supply chain efficiency. Keywords: Serialization, Pharmaceutical.
{"title":"Impact and overview of track and trace system and serialization in pharmaceutical industry","authors":"Dhavalkumar Patel, Devnaad Singh, Biraju Patel, C. Borkhataria","doi":"10.18231/J.IJPP.2021.008","DOIUrl":"https://doi.org/10.18231/J.IJPP.2021.008","url":null,"abstract":"An alleviation of patient wellness and safety, the pharmaceutical ecotechnology play crucial role by eliminating the threat of counterfeit drugs, medicines and drug adulteration. The numerous issue of supply chain such as production of inferior copy of branded product with label of the original brand name, the risk of putting wrong product into distribution, unauthorized distribution of branded product and lack of consistency across countries are now a days creating challenges for pharmaceutical manufacturers worldwide. The regulatory authorities of countries and pharmaceutical industries believe that serialization\u0000and product tracking could be the ultimate solution for these worldwide issues. Serialization system has the capacity to find out current and past locations of the product through entire supply chain. Hence, due to urgent necessity in today’s competitive environment, the implementation of this technology has found to be more effective to enhance counterfeit prevention, pilferage reduction and targeted recalls as well as improve security, visibility, synchronization and supply chain efficiency.\u0000\u0000Keywords: Serialization, Pharmaceutical.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"47-51"},"PeriodicalIF":1.5,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48503727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-09DOI: 10.1007/s10766-021-00702-5
Mengshan Yu, Guisheng Fan, Huiqun Yu, Liang Chen
{"title":"Location-based and Time-aware Service Recommendation in Mobile Edge Computing","authors":"Mengshan Yu, Guisheng Fan, Huiqun Yu, Liang Chen","doi":"10.1007/s10766-021-00702-5","DOIUrl":"https://doi.org/10.1007/s10766-021-00702-5","url":null,"abstract":"","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"49 1","pages":"715 - 731"},"PeriodicalIF":1.5,"publicationDate":"2021-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s10766-021-00702-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45835174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：